31 results about "Standard treatment" patented technology

Treatment of Cancer Methods for treatment of cancer, in particular soft tissue sarcomas (STS), are described, as well as compounds, compositions, and combined preparations for use in such methods. An effective amount of: a LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; a programmed cell death protein-1 (PD-1) pathway inhibitor; and radiotherapy, is administered to a subject. Optionally the subject has undergone, is undergoing, or is to undergo, surgery for treatment of the cancer. A clinical trial study is described in which a triple combination of LAG-3 derivative eftilagimod alpha, a PD-1 pathway inhibitor, and radiotherapy was administered. The combination was surprisingly effective in the treatment of STS in patients who have completed 10 weeks of treatment, followed by surgery 2-3 weeks later. A substantial number of near complete pathological responses were observed, which are rarely seen in STS patients with standard therapeutic approaches including radiotherapy.

This invention belongs to the field of biomedical technology, specifically relating to the discovery and application of biomarkers for predicting the efficacy of immunotherapy in nasopharyngeal carcinoma. This invention provides a reliable combination of 10-gene TLS biomarkers that can effectively predict the pathological TLS status in nasopharyngeal carcinoma tissue. This 10-gene TLS biomarker combination exhibits stable and significant prognostic predictive value: regardless of standard treatment or immunotherapy, a high TLS score can effectively identify patients with better survival outcomes (such as FFS, OS, and DMFS), providing important evidence for individualized risk assessment and treatment strategy selection.

The invention provides a pharmacist clinical ability assessment method and system based on multi-scene self-adaption, and relates to the technical field of pharmacist ability assessment, and the method comprises the steps: configuring a standard diagnosis and treatment process, a mapping rule of an operation event and a diagnosis and treatment step, and a reference weight vector of five ability dimensions for various assessment scenes in advance; performing multi-modal data acquisition on the assessment interaction process of the pharmacist and the virtual patient to obtain a dialogue text sequence; performing semantic coding and context modeling on the dialogue text sequence to obtain a global dialogue abstract vector; obtaining a five-dimensional score vector based on the dialogue text sequence, the diagnosis and treatment step sequence and the pharmaceutical knowledge graph; adopting an adaptive weight network to generate fusion weight vectors of five capability dimensions; and carrying out weighted aggregation on the five-dimensional score vector by using the fusion weight vector to obtain a comprehensive score, and outputting a structured evaluation report. According to the method, the defects of single evaluation scene, shallow scoring dimension and weight logic solidification in the prior art can be overcome.

The invention relates to an application of an anti-CD20 antibody drug conjugate or a drug combination thereof in preparation of a drug for treating recurrent or refractory non-Hodgkin lymphoma after receiving at least one standard treatment schedule, and the drug combination comprises the anti-CD20 antibody drug conjugate and at least one therapeutic agent, the anti-CD20 antibody drug conjugate or the drug combination therapy containing the anti-CD20 antibody drug conjugate has a better curative effect compared with the existing clinical second-line standard therapy.

The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid to administer to a patient in need thereof, comprising the steps of:(i) testing whether or not the patient has the poor metabolizer genotype; and(ii) if the patient does not have the poor metaboliser genotype, administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the standard therapeutic dose; and(iii) if the patient does have the poor metaboliser genotype, either(a) administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose below that of the standard therapeutic dose; or(b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.

The present disclosure relates generally to biomarker discovery and patient stratification, and more specifically to machine learning techniques for discovering relevant biomarkers using data collected as part of the standard-of-care (SoC), which can be used to identify a relevant patient population for a therapeutic with a known mechanism of action (MoA). An exemplary method for predicting activity of a molecular analyte of a patient comprises: training a first module of a machine learning model based on a plurality of medical images of a first cohort; training a second module of the machine learning model based on one or more molecular analyte data sets obtained from a second cohort; receiving a medical image from the patient; and predicting, using the trained first and second modules of the machine learning model, the activity of the molecular analyte from the medical image of the patient.

The invention relates to application and a method for treating tumor diseases by using a drug conjugate. Specifically, provided are uses and methods of biologically active conjugate of formula (I) in the treatment of neoplastic diseases, particularly preferably treating locally advanced or metastatic solid tumors, particularly non-small cell lung cancer, which are refractory to treat and cannot be resected by surgery, according to existing standards.

Currently, there is no cure for myasthenia gravis (MG), and standard treatment focuses on symptom relief with the use of steroids or immunosuppressants, which have only temporary effects and are associated with serious side effects such as an increased risk of infection and death. [Solution] This application generally relates to compositions comprising tolerance-immunomodified particles encapsulating myasthenia gravis (MG)-related antigens, methods for treating MG using tolerance-immunomodified nanoparticles encapsulating MG-related antigens, and processes for preparing tolerance-immunomodified nanoparticles encapsulating MG antigens.

Disclosed are methods of treatment, compositions and kits comprising endocannabinoid receptor (ECR) antagonist and an mTOR inhibitor for treating neoplasm in a subject in need thereof, and reducing drug resistance to standard treatment.

The present invention relates to a nucleic acid sequence encoding the transcription factor ESE3 / EHF or an isoform thereof, for use in the treatment of a cancer in a patient in need thereof and can be a mRNA or a DNA, in particular for use in the treatment of prostate cancer. The invention also relates to a plasmid, a viral vector or a pharmaceutical composition comprising, such nucleic acid sequence. In particular, the present invention is based on the use of plasmid DNA coding the full-length sequence of the gene ESE3 / EHF and to the use of in vitro transcribed (IVT) mRNA of ESE3 / EHF as gene therapy in aggressive prostate cancerESE3 / EHF is a transcription factor that is expressed in normal prostate but is lost in prostate tumors, particularly during the progression from indolent to aggressive tumors. The aim is to replace the ESE3 / EHF transcription factor using gene therapy approaches at the time the gene is reduced or lost. The invention also relates to the use of ESE3 / EHF replacement in combination therapy with androgen deprivation therapy (ADT), the standard treatment for metastatic prostate cancer, and other therapies, such as androgen receptor signalling inhibitors (ARSI), chemotherapeutics, molecular-targeted therapeutics, and immunotherapeutics.

NOVEL COMPOSITIONS FOR DISRUPTING BIOFILMS Abstract of the Disclosure Compositions and methods are provided for disrupting biofilms formed by microbial organisms. In accordance with one embodiment such compositions are used in conjunction with standard treatment for use on chronic wounds. In one embodiment the biofilm disrupting composition comprises a nuclease and aurine tricarboxylic acid. The biofilm disrupting compositions disclosed herein can be used in conjunction with a therapeutic pharmaceutical composition comprising standard antibiotics. NOVEL COMPOSITIONS FOR DISRUPTING BIOFILMS Abstract of the Disclosure 20 26 20 51 40 30 J un 2 02 6 N O V E L C O M P O S I T I O N S F O R D I S R U P T I N G B I O F I L M S 2 0 2 6 2 0 5 1 4 0 3 0 J u n 2 0 2 6 A b s t r a c t o f t h e D i s c l o s u r e

The invention belongs to the technical field of medicines, and particularly relates to application of nuezhenide G13 in preparation of a medicine or a medicine composition for treating or preventing ulcerative colitis. It is found for the first time that the nuezhenide G13 can significantly improve the pathological symptoms of UC on an in-vivo animal model, the curative effect of the nuezhenide G13 is even superior to that of a clinical first-line drug salazosulfapyridine, and the invention also discloses a unique action mechanism of the nuezhenide G13 for repairing the intestinal mucosal barrier, which is not reported before for the first time. According to the invention, the in-vivo drug effect of the ligustroside G13 is evaluated through a recognized DSS-induced mouse UC model. When the ligustroside G13 is used for treating UC of a human body, the ligustroside G13 shows superior performance exceeding that of clinical standard treatment drugs.

The invention discloses a marker, a kit and a prediction method for predicting the treatment effect of AIH (autoimmune hepatitis), the marker is JUNB protein, and the identifier of the JUNB protein in a UniProt database is UniProtID: P17535; the kit is used for detecting the JUNB protein. According to the method, the expression level of JUNB in the PBMC is detected, under the determined cut-off value, a complete biochemical response group and an insufficient response group of an AIH standard treatment scheme are efficiently and accurately distinguished, and objective and accurate data support is provided for clinicians to early recognize refractory patients and timely adjust treatment strategies. According to the present invention, with the application of the kit to predict the refractory patient of AIH, the accuracy is high, the missed diagnosis rate is zero, the sensitivity of the prediction method is high, the clinical missed diagnosis risk on the refractory patient is eliminated, and the safety and the reliability are high.

Methods of using biomarker levels to improve treatment outcome by A2R antagonists in oncology are provided. Embodiments of the present disclosure also provide methods of treating a subject with a cancer having high expression of the disclosed biomarkers with an A2R antagonist as well as methods of improving standard treatment outcomes in patients having high expression levels of the biomarkers.

The invention relates to an application of a medicine in treating tumor diseases. Specifically, the invention provides the application of the bioactive substance conjugate shown in the formula (I) in the treatment of tumor diseases, and the tumor diseases are particularly preferably used for treating local advanced or metastatic solid tumors which are difficult to treat and cannot be resected by surgery according to the existing standard. Comprise but are not limited to breast cancer, stomach cancer, lung cancer, ovarian cancer, urothelial cancer, esophageal cancer, liver cancer, colorectal cancer, cervical cancer, endometrial cancer, pancreatic cancer and brain tumor.

The application discloses a kind of standard diagnosis and treatment scheme automatic construction system of multiple typing of disease, it is characterized in that, comprising: data preprocessing module;ADRG grouping module;Core project automatic identification module;Regression tree grouping module.The present application technology combines clinical medical knowledge and machine learning method, identifies the standard treatment scheme of multiple typing under disease, forms disease knowledge base, to provide reference for the audit of fraud insurance case.The present application uses the medical knowledge of ADRG under the premise, uses some logical judgment to screen out the core project under disease to the medical data, uses regression tree to group important features.The grouping result and the clinical interpretability of the feature of grouping are strong, and the accuracy is also higher.In the process of grouping, both consider the project involved in diagnosis and treatment scheme, and can use model to realize efficient grouping.

Compositions and methods are provided for disrupting biofilms formed by microbial organisms. In accordance with one embodiment such compositions are used in conjunction with standard treatment for use on chronic wounds. In one embodiment the biofilm disrupting composition comprises a nuclease and aurine tricarboxylic acid. The biofilm disrupting compositions disclosed herein can be used in conjunction with a therapeutic pharmaceutical composition comprising standard antibiotics.

The objective of the present invention is to treat cancer in affected dogs by using interleukin-15, which plays a pivotal role in both innate immunity and acquired immunity. Specifically, the present invention relates to a composition for treating cancer in mammary tumor- or lymphoma-affected dogs, or an anticancer immune enhancer, comprising recombinant canine interleukin-15. The present invention also relates to the dosage and use of recombinant canine interleukin-15 in the treatment of cancer in mammary tumor- or lymphoma-affected dogs. The present invention can exhibit therapeutically effective anticancer- or anticancer immunity-enhancing efficacy by minimizing harmful effects or side effects after standard treatment in mammary tumor- or lymphoma-affected dogs by using recombinant canine interleukin-15.

The present invention concerns improved methods and compositions for neoadjuvant use of antibody-drug conjugates (ADCs) in cancer therapy, preferably ADCs comprising an anthracycline or camptothecin, more preferably SN-38 or pro-2-pyrrolinodoxorubicin (P2PDox). The ADC is administered as a neoadjuvant, prior to treatment with a standard anti-cancer therapy such as surgery, radiation therapy, chemotherapy, or immunotherapy. Neoadjuvant use of the ADC substantially improves the efficacy of standard anti-cancer therapy and may debulk a primary tumor or eliminate micrometasteses. In most preferred embodiments, neoadjuvant ADC in combination with a standard anti-cancer therapy is successful in treating cancers that are resistant to standard treatments, such as triple-negative breast cancer (TNBC).

The invention discloses application of AGGF1 as a drug target in treatment of idiopathic pulmonary fibrosis, and belongs to the technical field of drugs. Researches find that the angiogenic factor AGGF1 and polypeptide drugs thereof can effectively prevent and reverse idiopathic pulmonary fibrosis by inhibiting STING, NEMO and MAVS mediated DNA / RNA induction pathways, AGGF1 treatment depends on TRIM29, and the curative effect of AGGF1 is superior to that of a current standard treatment drug pirfenidone. The invention provides a new drug target and a novel therapy for the treatment of pulmonary fibrosis, especially idiopathic pulmonary fibrosis. The method disclosed by the invention is subsidized by a national key research and development plan project (2023YFA1800900).

The invention relates to the technical field of molecular markers, in particular to application of SOX4 in predicting the curative effect of inflammatory breast cancer. The detection kit provided by the invention can be used for detecting the expression level of SOX4 in the tumor tissue of an inflammatory breast cancer patient, so that the inflammatory breast cancer patient is accurately predicted through targeted HER2 overexpression standard treatment, namely the effect after TCbHP scheme treatment; after the kit disclosed by the invention is applied to clinical detection, the treatment effect of a patient can be evaluated before treatment, and a more positive and effective treatment scheme can be formulated for the patient with poor treatment effect, so that individualized treatment of the patient is realized, and the survival rate is increased.

This invention provides a system and method for discovering relevant biomarkers using data collected as part of standard of care (SoC). [Solution] A method for predicting the activity of a patient's molecular analytes includes training a first module of a machine learning model based on multiple medical images from a first cohort, training a second module of the machine learning model based on one or more molecular analyte datasets obtained from a second cohort, receiving medical images from the patient, and using the trained first and second modules of the machine learning model to predict the activity of a molecular analyte from the patient's medical images.

The application relates to the medical technical field, in particular to application of sulfasalazine in preparation of a medicine for treating primary biliary cholangitis (PBC) which is poorly responsive to ursodeoxycholic acid (UDCA), aiming at the clinical problem that about 40% of PBC patients are poorly responsive to the first-line drug UDCA, have high disease progression risk and limited second-line treatment options, and providing a new treatment use of the mature drug sulfasalazine. Through prospective clinical research, it is confirmed that, on the basis of UDCA standard treatment, combined use of sulfasalazine (1.5g / day, a treatment course of 48 weeks) can significantly improve liver biochemical indexes of UDCA non-responders, including alkaline phosphatase and gamma-glutamyltransferase, and 62.5% of the patients reach composite biochemical response. The application provides a new, effective, safe and highly accessible second-line treatment strategy for PBC patients who are poorly responsive to UDCA, and has a good clinical application prospect.

The application provides a set of biomarkers for predicting the benefit of nasopharyngeal carcinoma immunotherapy and application thereof, transcriptome data analysis of non-metastatic initial treatment of locally advanced nasopharyngeal carcinoma patients obtains a three-classification model using 318 genes as features based on nearest shrinkage centroid classification method, in the model, the event-free survival rate of patients of type 1 is significantly improved after receiving anti-PD-1 immunotherapy compared with the standard treatment group, the model can reflect the biological heterogeneity of nasopharyngeal carcinoma patients, can more accurately predict the immunotherapy benefit of nasopharyngeal carcinoma patients, and better guide clinical medication. The method for predicting the benefit of nasopharyngeal carcinoma immunotherapy can detect paraffin tissue samples, and does not depend on large sample quantity clustering, can type patients at a single sample level, has high feasibility and is easy to popularize, and has important significance for nasopharyngeal carcinoma immunotherapy.

The invention relates to a vesicle loaded with Bevacizumab and a preparation method and application thereof.The vesicle is formed by mixing cell membrane nano vesicles and platelet membrane nano vesicles which encode TIGIT genes, the mass ratio of the cell membrane nano vesicles to the platelet membrane nano vesicles is (1-10): 1, the vesicles encapsulate Bevacizumab, and the vesicles can specifically target liver and TZ, inhibit neovascularization and improve the activity of TZ. And the anti-tumor function of the CD8 + T cells is recovered. Research results show that BevatTPNV can effectively inhibit liver metastasis after MWA. Compared with a control group, the intrahepatic metastasis load is reduced by about 10 times, and the survival rate of mice within 70 days reaches 50%. The work is expected to establish a new standard treatment mode, and the combined immunotherapy after hepatic metastatic tumor ablation can be thoroughly changed.

The invention provides a group of biomarkers for predicting nasopharyngeal carcinoma immunotherapy benefit and application thereof, transcriptome data of a non-metastatic primary treatment local advanced nasopharyngeal carcinoma patient is analyzed to obtain a three-classification model which uses 318 genes as characteristics and is based on a recent systolic centroid classification method; compared with a standard treatment group, the event-free survival rate of a type 1 patient subjected to anti-PD-1 immunotherapy in the model is remarkably improved, the model can reflect the biological heterogeneity of the nasopharyngeal carcinoma patient, the immunotherapy benefit condition of the nasopharyngeal carcinoma patient can be more accurately predicted, and clinical medication can be better guided. According to the method for predicting nasopharynx cancer immunotherapy benefit, paraffin tissue sample detection can be utilized, large sample quantity clustering is not depended on, a patient can be subjected to typing at a single sample level, feasibility is high, popularization is easy, and the method has important significance on nasopharynx cancer immunotherapy.

The invention belongs to the technical field of biological medicines, and particularly relates to discovery and application of a marker for predicting the curative effect of nasopharyngeal carcinoma immunotherapy. The invention provides a reliable 10 gene TLS marker combination, which can effectively predict the pathological TLS state in nasopharyngeal carcinoma tissues. The 10 gene TLS marker combination shows stable and remarkable prognosis prediction value, patients with better survival outcomes (such as FFS, OS and DMFS) can be effectively recognized through high TLS scores no matter under standard treatment or immunotherapy, and an important basis is provided for individualized risk assessment and treatment strategy selection.

This application discloses a method and related products for analyzing drug safety and efficacy based on target trial simulation. The method preprocesses clinical data from patients with prostate disease to obtain standardized data; then, it simulates a target trial on the standardized data according to preset conditions to determine the simulation trial dataset and analysis parameter table. The simulation trial dataset is a set of standardized data used to simulate clinical trial analysis; the analysis parameter table is a set of parameter configurations recording the preset conditions used in the target trial simulation process; the preset conditions include inclusion / exclusion criteria, treatment grouping rules, follow-up rules, and bias control strategies; finally, it performs drug safety and efficacy analysis on the simulation trial dataset and analysis parameter table to obtain the drug safety and efficacy analysis results. This avoids the time-consuming, labor-intensive, and difficult-to-conduct aspects of traditional clinical trials, achieving high efficiency and low cost while providing relatively rigorous and reliable results to support the needs of rapid clinical decision-making.

Methods of using biomarker levels to improve treatment outcome by CD73 inhibitors in oncology are provided. Embodiments of the present disclosure also provide methods of treating a subject with a cancer having high expression of the disclosed biomarkers with a CD73 inhibitor as well as methods of improving standard treatment outcomes in patients having high expression levels of the biomarkers.

The invention discloses an application of a combination of an anti-CD20 antibody drug conjugate and at least one therapeutic agent in preparation of a drug for treating recurrent or refractory non-Hodgkin lymphoma after receiving at least one standard therapeutic schedule. The combined therapy of the anti-CD20 antibody drug conjugate and at least one therapeutic agent has a better curative effect than the existing clinical second-line standard therapy.